Rezafungin (Rezzayo) for Invasive Candida Infections

Found an issue? Give us feedback

The Medical Letter o...arrow_drop_down

The Medical Letter on Drugs and Therapeutics

Article . 2024 . Peer-reviewed

Data sources: Crossref

The Medical Letter on Drugs and Therapeutics

Article . 2024

Data sources: Europe PubMed Central

Rezafungin (Rezzayo) for Invasive Candida Infections

descriptionPublicationkeyboard_double_arrow_right Article 24 Jun 2024Publisher:The Medical Letter, Inc.Journal:The Medical Letter on Drugs and Therapeutics, volume 66, pages 101-104 (eissn: 1523-2859,

Copyright policy )

doi: 10.58347/tml.2024.1705d

pmid: 38905526

Rezafungin (Rezzayo) for Invasive Candida Infections

- Summary
- Subjects
- Metrics

Abstract

The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug to become available in the US in more than 15 years for treatment of systemic Candida infections.

Keywords

Echinocandins, Antifungal Agents, Humans, Candidiasis, Invasive

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average